1-6 of 6
Jean Cheung
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase (Ph) 2 Study of TL-895, a Highly Selective, Novel Covalent BTK Inhibitor (BTKi), in Patients (pts) with Treatment-Naïve (TN) and Relapsed/Refractory (R/R) BTKi-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

John C. Byrd, Dariusz Woszczyk, Arpad Illes, Wojciech Jurczak, Dominik Chraniuk, Krzysztof Giannopoulos, Nataliia Mikhailova, Peter Illconzai, Seema A Bhat, Nataliya Romanyuk, Ganna Usenko, Olha Kuchkova, Jason Chandler, Elizabeth Bilotti, Annalise Shen, Jean Cheung, Srdan Verstovsek, Jesse McGreivy, Wayne Rothbaum, Maciej Kaźmierczak
Journal: Blood
Blood (2023) 142 (Supplement 1): 4634.
https://doi.org/10.1182/blood-2023-186517
Published: 2023
Journal Articles

Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies

Sara Elgamal, Tracy Clevenger, Michael Gulrajani, Jean Cheung, Erin G. Jeremy, Sydney Fobare, Shelley Orwick, Ellen J. Sass, Erin Hertlein, Karilyn T. Larkin, Todd Covey, Wayne P. Rothbaum, John C. Byrd
Journal: Blood
Blood (2022) 140 (Supplement 1): 5936–5938.
https://doi.org/10.1182/blood-2022-159568
Published: 2022
Journal Articles

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Clinical Trials & Observations
Clare Sun, Pia Nierman, Ellen K. Kendall, Jean Cheung, Michael Gulrajani, Sarah E. M. Herman, Christopher Pleyer, Inhye E. Ahn, Maryalice Stetler-Stevenson, Constance M. Yuan, Irina Maric, Erika M. Gaglione, Hailey M. Harris, Stefania Pittaluga, Min Hui Wang, Priti Patel, Mohammed Z. H. Farooqui, Raquel Izumi, Ahmed Hamdy, Todd Covey, Adrian Wiestner
Journal: Blood
Blood (2020) 136 (1): 93–105.
https://doi.org/10.1182/blood.2019003715
Published: 2020
Includes: Supplemental data
Journal Articles

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Elena Bibikova, Brian Law, Tracy Clevenger, PhD, Jean Cheung, MS, Gary De Jesus, Michael Gulrajani, Kyoko Yamaguchi, Phuong Do, Kathleen Burke, PhD, Graham Brock, PhD, Veerendra Munugalavadla, PhD, Melanie M. Frigault, PhD, John C. Byrd, MD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD, Todd Covey
Journal: Blood
Blood (2019) 134 (Supplement_1): 2571.
https://doi.org/10.1182/blood-2019-128872
Published: 2019
Journal Articles

Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling

Anfal A. Alsadhan, Jean Cheung, Michael Gulrajani, Erika M. Cook, Stefania Pittaluga, MD PhD, Theresa Davies-Hill, Raquel Izumi, PhD, Clare C. Sun, MD, Todd Covey, PhD, Adrian Wiestner, MD, Sarah E. M. Herman, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4401.
https://doi.org/10.1182/blood-2018-99-110391
Published: 2018
Journal Articles

Pharmacodynamic Evaluation of Acalabrutinib in Relapsed/Refractory and Treatment-Naive Patients with Chronic Lymphocytic Leukemia (CLL) in the Phase 1/2 ACE-CL-001 Study

Todd Covey, PhD, Michael Gulranjani, Jean Cheung, Elena Bibikova, Tracy Clevenger, Fanny Krantz, Karen Pan, Kyoko Yamaguchi, Anouk De Jong, Bart Van Lith, Diana Mittag, Raquel Izumi, PhD, John C. Byrd, MD, William G Wierda, MD PhD, Susan M. O'Brien, MD, Richard R. Furman, MD, Allard Kaptein, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1741.
https://doi.org/10.1182/blood.V130.Suppl_1.1741.1741
Published: 2017